425: BioNTech Updates CureVac Offer, Reports Q3 Loss Amid Strategic Shifts

BioNTech SE updated its public exchange offer for CureVac N.V. shares and reported a net loss of €28.7 million for Q3 2025, driven by settlement expenses and declining COVID-19 vaccine revenues, despite strategic partnership gains.

Summary

• BioNTech SE updated its exemption document for the public exchange offer to CureVac N.V. shareholders, proposing 15,061,575 newly registered American Depositary Shares (ADSs) in exchange for all issued ordinary shares of CureVac.
• The offer, which commenced on October 22, 2025, will expire on December 3, 2025, and is subject to conditions including at least 80% of CureVac shares tendered.
• Reported a net loss of €28.7 million for the three months ended September 30, 2025, a decrease from a net profit of €198.1 million in the same period of 2024.
• For the nine months ended September 30, 2025, the net loss was €831.1 million, an improvement from a net loss of €924.8 million in the prior year period.
• Total revenues for Q3 2025 increased by 22% to €1,518.9 million, primarily due to €613.0 million from an out-licensing agreement with Bristol-Myers Squibb (BMS).
• COVID-19 vaccine revenues decreased by 23% to €853.3 million in Q3 2025 and by 13% to €1,139.6 million for the nine months ended September 30, 2025.
• Incurred €678.5 million ($790.0 million) in other operating expenses related to settlement agreements with GSK/CureVac.
• Cash and cash equivalents stood at €10,092.9 million as of September 30, 2025, with total cash, cash equivalents, and security investments at €16,704.9 million.

Sentiment

Score: 4

Explanation: The filing presents a mixed financial picture with a net loss for the quarter and full-year forecast, driven by declining COVID-19 vaccine sales and significant settlement expenses. While strategic partnerships and pipeline progress in oncology are positive, the immediate financial performance and ongoing legal challenges weigh negatively on sentiment.

Positives

• Total revenues increased by 22% to €1,518.9 million in Q3 2025, driven by a significant out-licensing deal.
• Secured a global strategic partnership with Bristol-Myers Squibb (BMS) for co-development and co-commercialization of pumitamig (BNT327/BMS986545), including an upfront payment of $1.5 billion and potential for up to $7.6 billion in milestone payments.
• Net loss for the nine months ended September 30, 2025, decreased by 10% to €831.1 million compared to €924.8 million in the prior year.
• Research and development expenses for non-COVID-19 vaccine programs increased by 21% in Q3 2025 and 7% for the nine months, indicating continued investment in the oncology pipeline.
• Reported positive topline results from a Phase 3 study for the LP.8.1-adapted COVID-19 vaccine in adults 65+ and 18-64 with risk conditions, showing robust neutralizing antibodies and a consistent safety profile.
• Presented positive data from the BNT111 trial in advanced melanoma at the 2025 ESMO Congress, showing deep and durable anti-tumor responses and a positive impact on long-term survival (37% alive at 24 months, 21% progression-free).
• First patient dosed in a new cohort evaluating BNT116 in combination with BNT324/DB-1311 for NSCLC.
• Presented data for autogene cevumeran at ESMO 2025, showing durable immune responses and a trend of improved OS in specific patient populations.
• BNT327 (pumitamig) Phase 2 interim data in ES-SCLC showed encouraging anti-tumor responses and progression-free survival with a manageable safety profile.
• China's NMPA granted Breakthrough Therapy Designation for gotistobart for squamous NSCLC.
• Initiated a Phase 3 trial for BNT323/DB-1303 in HER2-expressing recurrent endometrial cancer.
• The U.S. Patent Trial and Appeal Board (PTAB) found all challenged claims of Moderna's U.S. Patent Nos. 10,933,127 and 10,702,600 to be unpatentable and thus invalid.
• The Ladewig securities class action complaint was dismissed in its entirety, and the appeal deadline passed without action from plaintiffs.

Negatives

• Reported a net loss of €28.7 million in Q3 2025, a significant decline from a net profit of €198.1 million in Q3 2024.
• COVID-19 vaccine revenues decreased by 23% in Q3 2025 and 13% for the nine months ended September 30, 2025, primarily due to lower dose volumes.
• Incurred substantial other operating expenses of €678.5 million ($790.0 million) related to settlement agreements with GSK/CureVac.
• Operating profit shifted to a loss of €46.9 million in Q3 2025 from a profit of €10.5 million in Q3 2024.
• Finance result decreased by 52% in Q3 2025 and 47% for the nine months ended September 30, 2025, mainly due to lower interest income and negative foreign exchange differences.
• Incurred a one-time impairment loss of €85.4 million on the product candidate BNT323/DB-1303 due to a revision of commercial forecast assumptions.
• The development program for BNT312/GEN1042 in combination with pembrolizumab and chemotherapy has been discontinued due to strategic evaluation.
• Total equity decreased by €933.8 million from December 31, 2024, to September 30, 2025, mainly due to the net loss.
• The company does not expect to report a positive net income figure for the 2025 financial year.

Risks

• Demand for COVID-19 vaccines is expected to continue to decrease, impacting revenues which are currently heavily dependent on these sales.
• Challenges related to the production of COVID-19 vaccines due to changing market dynamics.
• Inability to increase marketing and sales capabilities independently or through third parties may hinder effective commercialization of product candidates.
• Government policies (manufacturing, export controls, tariffs) and negative public perception regarding vaccines and mRNA-based therapeutics could severely impact sales.
• Long-term sustainable profitability is difficult to achieve and maintain, highly dependent on factors like new virus variants, regional policy changes, and public health measures.
• Ability to use net operating losses (NOLs) and research and development credits to offset future taxable income may be limited and uncertain.
• Pending and future tax audits, disputes with tax authorities, and changes in tax law could lead to additional tax liabilities.
• Failure to appropriately account for complex terms in collaboration and licensing agreements could require restatement of financial statements.
• Dependence on the successful development, regulatory approval, and commercialization of product candidates based on technology platforms.
• Ongoing intellectual property disputes with CureVac, Moderna, Arbutus/Genevant, GSK, and Promosome, with uncertain outcomes and potential for significant financial impact.
• Increasing number of product-related disputes and shareholder claims.
• Need for substantial additional financing to achieve goals, with failure to obtain it potentially forcing delays or termination of programs.

Future Outlook

Do not expect to report a positive net income figure for the 2025 financial year. Forecasted revenues for 2025 are expected to be between €2.6 billion and €2.8 billion, primarily from commercial sales of the COVID-19 vaccine and a collaboration agreement. Research and development expenses for 2025 are projected to be between €2.0 billion and €2.2 billion, with a focus on late-stage oncology development and continued COVID-19 vaccine development, including a combination with flu protection. Sales, general and administrative expenses for 2025 are anticipated to be between €550.0 million and €650.0 million. Operating investments in property, plant, and equipment and intangible assets for 2025 are expected to be between €200.0 million and €250.0 million, excluding any investments by CureVac post-acquisition.

Management Comments

• Do not expect to report a positive net income figure for the 2025 financial year.
• Confirm that we do not expect to report a positive net profit / (loss) figure for the year 2025.
• We anticipate to continue using the potential of our pipeline and focus investments in research and development for late-stage development in oncology.
• We also intend continuing to develop our COVID-19 vaccine, including in combination with flu protection.
• We expect to increase our expenditure on research and development while, in line with our cost-conscious portfolio optimization strategy, we expect to reduce it outside our focus area.
• The impairment does not impact our strategy to bring BNT323/DB-1303 to market. We continue to view this product candidate as a foundational opportunity to establish our commercial infrastructure, paving the way for future launches.

Industry Context

The biopharmaceutical industry is experiencing a shift from pandemic-driven demand for COVID-19 vaccines towards a renewed focus on oncology and other serious diseases. BioNTech's strategic partnership with BMS for a bispecific antibody candidate and increased R&D investment in non-COVID-19 programs align with this trend, aiming to diversify revenue streams beyond the declining COVID-19 vaccine market. The ongoing patent litigations highlight the intense competitive landscape and intellectual property challenges within the mRNA and broader biopharma sectors.

Comparison to Industry Standards

• The decline in COVID-19 vaccine revenues is consistent with broader industry trends as the pandemic transitions to an endemic phase and global vaccination campaigns slow. Many vaccine manufacturers are seeing reduced demand compared to peak pandemic levels.
• The strategic shift towards oncology, particularly with bispecific antibodies and ADCs like pumitamig (BNT327) and BNT323/DB-1303, aligns with major pharmaceutical companies' focus on high-value therapeutic areas with significant unmet medical needs. For example, companies like AstraZeneca, Genentech (Roche), and Seagen (now Pfizer) have made substantial investments and acquisitions in the ADC space, indicating a competitive but promising market.
• The upfront payment of $1.5 billion and potential $7.6 billion in milestones from the BMS partnership for pumitamig are substantial, reflecting the high valuation of late-stage oncology assets in the current market, comparable to other major biopharma collaborations.
• The ongoing and numerous patent litigations (e.g., with Moderna, CureVac, GSK) are common in the highly innovative and competitive mRNA and vaccine technology sectors, where intellectual property is fiercely protected. This is similar to past patent disputes seen with other blockbuster drugs and technologies.
• The impairment of BNT323/DB-1303 due to revised commercial forecast assumptions, despite continued strategic importance, reflects the inherent risks and uncertainties in drug development and commercialization, a common occurrence across the industry.

Management Changes

Corporate Governance

Legal Proceedings

• Alnylam Proceedings: Lawsuits alleging infringement of multiple U.S. patents related to cationic lipids in Comirnaty. Consolidated into a single proceeding. Alnylam voluntarily dismissed one patent. Litigation stayed, and a final judgment of noninfringement was entered on July 30, 2025. A settlement agreement and covenant not to sue was entered into on August 29, 2025, concluding the case.
• CureVac Proceedings (Germany): Multiple lawsuits alleging Comirnaty's infringement of European patents and German Utility Models. Some proceedings stayed pending validity decisions. CureVac waived DE575 and DE123. Oral hearings for EP668 and EP755 infringement are scheduled for January 27, 2026 (postponed from Nov 6, 2025), with GSK seeking to intervene. BioNTech filed nullity and cancellation actions; EP122 was nullified (appealed by CureVac), DE961 and DE974 were cancelled (appealed by CureVac), and a preliminary opinion for DE130 indicates it is likely to be cancelled.
• CureVac Proceedings (United States): BioNTech and Pfizer filed a declaratory judgment action. CureVac filed counterclaims asserting infringement of multiple U.S. patents. A settlement agreement was reached on August 7, 2025, resolving the pending patent litigation in the United States and setting a framework for resolving disputes outside the U.S. (subject to CureVac acquisition).
• Moderna Proceedings (Germany): Lawsuit alleging Comirnaty's infringement of EP949 and EP565. EPO Opposition Division revoked EP565; Moderna appealed. EPO Boards of Appeal issued a preliminary opinion that EP565 is likely invalid. Düsseldorf Regional Court found infringement of EP949; BioNTech and Pfizer appealed.
• Moderna Proceedings (United Kingdom): Lawsuit alleging Comirnaty's infringement of EP949 and EP565. UK High Court found EP565 invalid and EP949 valid and infringed. UK Appeals Court denied Moderna's appeal for EP565, making its revocation final. UK Court of Appeal upheld EP949 validity; BioNTech applied for permission to appeal to the UK Supreme Court.
• Moderna Proceedings (United States): U.S. District Court litigation stayed pending inter partes review. PTAB found all challenged claims of Moderna's U.S. Patent Nos. 10,933,127 and 10,702,600 to be unpatentable and thus invalid. Moderna appealed.
• Moderna Proceedings (Netherlands, Ireland, Belgium): Lawsuits alleging Comirnaty's infringement of EP949 and EP565. The Hague Court found EP949 invalid; Moderna appealed. Cases in Ireland and Belgium stayed pending EPO outcomes or joint request.
• Arbutus and Genevant Proceedings: Lawsuit alleging infringement of U.S. patents related to lipid nanoparticle technology in Comirnaty. Currently pending.
• GlaxoSmithKline Proceedings (United States, Ireland, Unified Patent Court, United Kingdom): Multiple lawsuits alleging Comirnaty's infringement of various U.S. and European patents related to cationic lipids. All proceedings are currently pending. BioNTech and Pfizer filed a revocation action in the UK.
• Promosome Proceedings: Lawsuit alleging Comirnaty infringes EP 2 401 365 in the UPC Munich Division. Currently pending, with an oral hearing scheduled for May 2026.
• Ladewig Proceedings: Securities class action complaint alleging violations of the Exchange Act. Dismissed in its entirety by the U.S. District Court for the Southern District of New York on September 30, 2025. Plaintiffs did not file an appeal by the October 30, 2025 deadline.

Related Party Transactions

• ATHOS KG and entities controlled by it (sole shareholder of AT Impf GmbH, a 5% shareholder) provide rental and property management activities and sell property, plant and equipment. No significant impact on Q3 2025 financials.
• Members of the Management Board and Supervisory Board are key management personnel. No significant impact on Q3 2025 financials.

Stakeholder Impact

• Shareholders: Impacted by the CureVac tender offer (potential dilution, strategic expansion), Q3 net loss, full-year loss forecast, and ongoing legal risks. Positive pipeline developments and strategic partnerships offer long-term potential.
• CureVac Shareholders: Directly impacted by the public exchange offer, which proposes an exchange of CureVac shares for BioNTech ADSs.
• Employees: Biotheus acquisition added over 300 employees. Pipeline prioritization and restructuring led to employee-related obligations.
• Customers: COVID-19 vaccine customers are experiencing declining demand, while new product candidates in oncology aim to address unmet medical needs.
• Partners (BMS, Pfizer, Genmab, DualityBio): Collaboration agreements are central to BioNTech's strategy, with shared development costs and profit/loss. The BMS partnership is a significant revenue driver.
• Creditors: Financial position remains strong with substantial cash and security investments, but ongoing losses and legal liabilities are factors to monitor.

Next Steps

• CureVac N.V. public exchange offer to expire on December 3, 2025.
• Continue to jointly develop and commercialize pumitamig (BNT327/BMS986545) with BMS.
• File a biologics license application (BLA) for BNT323/DB-1303 in second-line endometrial cancer in 2026, subject to regulatory feedback.
• Continue clinical trials for various oncology and infectious disease product candidates, including BNT116, autogene cevumeran, BNT327, and COVID-19/Influenza combination vaccines.
• Ongoing appeals and hearings for patent infringement proceedings with Moderna, CureVac, GSK, and Promosome.
• Oral hearing regarding the validity of CureVac's DE130 before the German Patent and Trademark Office scheduled for December 8, 2025.
• Oral hearing on the appeal of the nullification of CureVac's EP122 scheduled for July 2026.
• Oral hearing on the appeal of Moderna's EP949 scheduled for September 2026.

Key Dates

Recommendation

The filing presents a complex picture. While BioNTech is making significant strategic moves, such as the CureVac tender offer and the BMS partnership, and showing progress in its oncology pipeline, the immediate financial performance is concerning. The net loss for Q3 2025 and the full-year loss forecast, coupled with declining COVID-19 vaccine revenues and substantial settlement expenses, indicate headwinds. The numerous ongoing patent litigations also introduce significant uncertainty and potential future liabilities. Investors should hold, awaiting clearer signs of profitability from the diversified pipeline and resolution of legal challenges, while acknowledging the strong cash position and strategic growth initiatives.

Keywords

BioNTech, CureVac, Tender Offer, SEC Filing, Q3 2025 Earnings, Financial Results, COVID-19 Vaccine, mRNA, Oncology, Bispecific Antibody, Antibody-Drug Conjugate, Pumitamig, BNT327, Bristol-Myers Squibb, BMS, Pipeline, Clinical Trials, Patent Litigation, GSK, Moderna, Alnylam, Biotechnology, Pharmaceuticals, Immunotherapy, Financial Performance, Risk Factors